Genetic PEGylation

Genetic PEGylation

Polyethylene glycol (PEG) was genetically incorporated into a polypeptide. Stop-anticodon-containing tRNAs were acylated with PEG-containing amino acids and were then translated into polypeptides corresponding to DNA sequences containing the stop codons. The molecular weights of the PEG used were 170, 500, 700, 1000, and 2000 Da, and the translation was confirmed by mass spectrometry. The PEG i...

PEGylation of therapeutic proteins.

Since the first PEGylated product was approved by the Food and Drug Administration in 1990, PEGylation has been widely used as a post-production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins. Applicability and safety of this technology have been proven by use of various PEGylated pharmaceuticals for many years. It is expected t...

Supramolecular PEGylation of biopharmaceuticals.

The covalent modification of therapeutic biomolecules has been broadly explored, leading to a number of clinically approved modified protein drugs. These modifications are typically intended to address challenges arising in biopharmaceutical practice by promoting improved stability and shelf life of therapeutic proteins in formulation, or modifying pharmacokinetics in the body. Toward these obj...

Drug delivery: Relieving PEGylation.

Pegylation Prevents Phospho-Ibuprofen Hydrolysis

Previous studies in rats and monkeys have shown that b2selective nicotinic acetylcholine receptor (nAChR) agonists reduce L-Dopa–induced dyskinesias (LIDs). Because rodent studies also suggested an involvement of a7 nAChRs in LIDs, the authors tested the effect of the potent, selective a7 agonist, ABT-107 [5-(6[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy] pyridazin-3-yl)-1H-indole]. MPTP (1-methyl-4-ph...